Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | CES2 | O00748 | 3/20 | 0.56 |
| ▸ | CES1 | P23141 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ERN1 | O75460 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14454102 | 0.88 | POLB (0.50) | TDP1CES2CES1POLBLMNA | |
| SCHEMBL11535241 | 0.87 | ERN1 (0.50) | TDP1CES2CES1POLBERN1 | |
| SCHEMBL2227942 | 0.86 | POLB (0.53) | TDP1CES2CES1POLBERN1 | |
| SCHEMBL3810969 | 0.86 | POLB (0.49) | TDP1CES2CES1POLBERN1 | |
| SCHEMBL7453721 | 0.83 | POLB (0.47) | TDP1CES2CES1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL6394591 | 0.82 | POLB (0.46) | TDP1CES2CES1POLBKMT2A | |
| SCHEMBL28114934 | 0.80 | KMT2A (0.53) | TDP1CES2CES1POLBERN1 | |
| SCHEMBL8570972 | 0.80 | POLB (0.42) | TDP1CES2CES1POLBERN1 | |
| SCHEMBL16485994 | 0.79 | TDP1 (0.51) | TDP1CES2CES1POLBLMNA | |
| SCHEMBL20812006 | 0.79 | TDP1 (0.51) | TDP1CES2CES1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | claimed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | claimed |
| WO-2024160276-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | claimed |
| US-5846990-A | Substituted biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB CO. (US) | 1998-12-08 | — | — | US | claimed |
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2024160276-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| CN-115636764-B | Synthesis method of benzamide compound | 广东省科学院化工研究所 | 2024-03-12 | — | — | CN | disclosed |
| CN-115636764-A | Synthetic method of benzamide compound | 广东省科学院化工研究所 | 2023-01-24 | — | — | CN | disclosed |
| US-20130281476-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281476-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | TDP1 4014/4885CES2 978/4885CES1 917/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | TDP1 2006/4885CES2 3346/4885CES1 1553/4885 |
| US-20240398811-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | EZH2, BMI1, EZH1 | TDP1 2355/4885CES2 4243/4885CES1 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.